Search

Corcept Therapeutics Inc

Fermé

SecteurSoins de santé

74.19 1.2

Résumé

Variation du prix de l'action

24h

Actuel

Min

71.31

Max

76.23

Chiffres clés

By Trading Economics

Revenu

75M

43M

Ventes

91M

256M

P/E

Moyenne du Secteur

178.8

51.78

BPA

0.36

Marge bénéficiaire

16.782

Employés

730

EBITDA

91M

47M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+127.77% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.1B

8.7B

Ouverture précédente

72.99

Clôture précédente

74.19

Corcept Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 nov. 2026, 21:01 UTC

Corcept Therapeutics shares are significantly lower amid high market volume, trading well below its 20-day moving average and nearing the lower end of its one-month range.

9 nov. 2026, 21:07 UTC

Corcept Therapeutics is trading higher, reflecting broader market gains amid positive sentiment from Federal Reserve officials and unusually high trading volume today.

6 nov. 2026, 20:52 UTC

News

Corcept Therapeutics shares are advancing after reporting a third-quarter net income of $126.78 million and diluted EPS of $1.01, despite earlier session pullbacks.

5 nov. 2026, 21:03 UTC

News

Selling pressure after 13.16k shares sold, lower sales guidance reaffirmed.

4 nov. 2026, 21:02 UTC

News

Corcept Therapeutics' Overweight rating was reaffirmed by Piper Sandler, which raised its price target to $173, despite disappointing revenue guidance for 2026.

3 nov. 2026, 23:01 UTC

News

Corcept Therapeutics reported Q3 revenue of $340.5 million and net income of $126.8 million, but reiterated full-year guidance of $1.1 billion to $1.2 billion.

2 nov. 2026, 21:09 UTC

Corcept Therapeutics shares are declining, continuing a trend of modest losses since Friday, as the broader market also experiences its fifth consecutive session of declines.

30 oct. 2026, 20:02 UTC

Corcept Therapeutics shares are sharply lower, reversing a trend of higher daily closes observed in recent sessions.

28 oct. 2026, 19:51 UTC

Corcept Therapeutics shares are declining, trading significantly below its 20-day moving average and near the lower end of its one-month range.

27 oct. 2026, 19:36 UTC

Corcept Therapeutics shares are advancing, having regained ground after pulling back earlier in the session, with a slight cumulative return since Monday's close.

26 oct. 2026, 23:21 UTC

Corcept Therapeutics Inc is trading lower in after-hours, remaining near the lower end of its one-month range and significantly below its 20-day moving average.

23 oct. 2026, 23:51 UTC

Corcept Therapeutics Inc is rising in after-market trading, recovering from an earlier dip to its highest point of the day despite recent declines.

22 oct. 2026, 20:02 UTC

Corcept Therapeutics Inc shares fell sharply, breaking from a recent trend of higher daily closes and indicating a downward shift in momentum.

20 oct. 2026, 20:08 UTC

News

Corcept Therapeutics shares gained following a report recommending hypercortisolism screening in type 2 diabetes, citing positive results from its CATALYST study on mifepristone.

16 oct. 2026, 20:01 UTC

Corcept Therapeutics Inc shares fell sharply, marking a notable decline and extending a streak of four consecutive sessions closing lower.

15 oct. 2026, 20:02 UTC

Corcept Therapeutics Inc shares are declining, having reached their lowest point around mid-afternoon after an early peak earlier in the session.

14 oct. 2026, 19:53 UTC

Corcept Therapeutics Inc shares fell sharply, continuing a downward trend since Tuesday's close, despite peaking in the late morning.

9 oct. 2026, 19:55 UTC

Corcept Therapeutics Inc is trading higher, having gained notably since Thursday's close and currently positioned above its 20-day moving average.

7 oct. 2026, 19:35 UTC

Corcept Therapeutics Inc is trading modestly higher, positioned significantly above its 20-day moving average and near the upper end of its one-month range.

6 oct. 2026, 23:55 UTC

Corcept Therapeutics Inc is trading higher in after-market hours, remaining above its 20-day moving average following a significant U.S. trade deficit of $105.6 billion in August.

5 oct. 2026, 20:01 UTC

Corcept Therapeutics Inc is trading sharply higher with unusually high share volume, nearing the upper end of its one-month trading range.

1 oct. 2026, 20:08 UTC

Corcept Therapeutics Inc shares fell sharply, declining from Wednesday's close and reaching a low before slightly recovering, remaining in the middle of its one-month trading range.

30 sept. 2026, 20:01 UTC

Corcept Therapeutics Inc is seeing higher trading activity with increased market volume and has gained ground since Tuesday, reaching a session high today.

29 sept. 2026, 20:07 UTC

Corcept Therapeutics Inc shares fell, continuing a trend with four consecutive sessions down since Monday, despite an earlier brief rebound.

28 sept. 2026, 19:34 UTC

Corcept Therapeutics Inc shares fell sharply amid a broader market downturn, coinciding with significant declines in major tech stocks and rising inflation concerns.

25 sept. 2026, 19:15 UTC

Corcept Therapeutics Inc shares fell sharply after an early high, reflecting a notable decline amid mixed broader market signals and flat U.S. durable goods orders.

24 sept. 2026, 23:06 UTC

Corcept Therapeutics Inc is trading lower during after-market hours, reflecting a broader market decline despite some recovery from earlier lows.

23 sept. 2026, 20:04 UTC

News

Corcept Therapeutics shares fell following the announcement of Sean Maduck's retirement as President of Endocrinology, with Justin Gunn set to take over.

22 sept. 2026, 19:34 UTC

News

Corcept Therapeutics' stock is advancing after the European drug regulator recommended approval for its cancer therapy, relacorilant, based on positive Phase 3 trial data.

21 sept. 2026, 20:06 UTC

Corcept Therapeutics Inc is advancing, maintaining significant gains since Friday's close, despite earlier pulling back from a session high.

Comparaison

Variation de prix

Corcept Therapeutics Inc prévision

Objectif de Prix

By TipRanks

127.77% hausse

Prévisions sur 12 Mois

Moyen 165.75 USD  127.77%

Haut 173 USD

Bas 161 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat